PTPN11 and Netherton syndrome: Because of the location of SHP2 on the mitochondria and its numerous disruptive effects, as discussed here, future research should focus on identifying potent pharmacological regulators that compete with SHP2 ligands/substrates, as this may be critical for alleviating complications in NS/NSML patients.